Last reviewed · How we verify
Tecemotide (L-BLP25)
Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen.
Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen. Used for Non-small cell lung cancer (NSCLC), stage IIIB/IV, Advanced or metastatic non-small cell lung cancer.
At a glance
| Generic name | Tecemotide (L-BLP25) |
|---|---|
| Also known as | Stimuvax, EMD531444, L-BLP25, BLP25 Liposome Vaccine, BLP25 liposome vaccine |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Cancer vaccine |
| Target | MUC1 (mucin 1) tumor-associated antigen |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tecemotide (L-BLP25) is a peptide vaccine consisting of a 25-amino acid peptide derived from the MUC1 tumor-associated antigen conjugated to a lipopeptide adjuvant. It is designed to activate both CD4+ and CD8+ T-cell responses against MUC1-expressing tumor cells. The vaccine approach aims to generate durable anti-tumor immunity in patients with advanced cancer.
Approved indications
- Non-small cell lung cancer (NSCLC), stage IIIB/IV
- Advanced or metastatic non-small cell lung cancer
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Myalgia
Key clinical trials
- BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE2)
- Tecemotide (L-BLP25) in Prostate Cancer (PHASE2)
- L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases (PHASE2)
- Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer (PHASE3)
- Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (PHASE1)
- Tecemotide (L-BLP25) in Rectal Cancer (PHASE2)
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (PHASE3)
- Common Safety Follow-up Trial of Tecemotide (L-BLP25) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tecemotide (L-BLP25) CI brief — competitive landscape report
- Tecemotide (L-BLP25) updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI